CorMedix Inc (CRMD)vsModerna Inc (MRNA)
CRMD
CorMedix Inc
$7.83
-1.70%
HEALTHCARE · Cap: $609.91M
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 382% more annual revenue ($2.23B vs $462.25M). CRMD leads profitability with a 40.5% profit margin vs -141.4%. CRMD earns a higher WallStSmart Score of 74/100 (B).
CRMD
Strong Buy74
out of 100
Grade: B
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CRMD.
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 41 in profit
Keeps 41 of every $100 in revenue as profit
Strong operational efficiency at 42.1%
Revenue surging 156.5% year-over-year
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CRMD
The strongest argument for CRMD centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 40.5% and operating margin at 42.1%. Revenue growth of 156.5% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : CRMD
The primary concerns for CRMD are Altman Z-Score, Market Cap, Piotroski F-Score.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
CRMD profiles as a growth stock while MRNA is a turnaround play — different risk/reward profiles.
CRMD carries more volatility with a beta of 1.50 — expect wider price swings.
CRMD is growing revenue faster at 156.5% — sustainability is the question.
CRMD generates stronger free cash flow (86M), providing more financial flexibility.
Bottom Line
CRMD scores higher overall (74/100 vs 21/100), backed by strong 40.5% margins and 156.5% revenue growth. MRNA offers better value entry with a 70.0% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CorMedix Inc
HEALTHCARE · BIOTECHNOLOGY · USA
CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. The company is headquartered in Berkeley Heights, New Jersey.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?